# PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC

> **NCT06742424** · PHASE2 · RECRUITING · sponsor: **West China Hospital** · enrollment: 36 (estimated)

## Conditions studied

- Hepato Cellular Carcinoma (HCC)

## Interventions

- **DRUG:** PD-L1 antibody
- **DRUG:** Bevacizumab
- **PROCEDURE:** HAIC-FOLFOX

## Key facts

- **NCT ID:** NCT06742424
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-07-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06742424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06742424, "PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT06742424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*